Use of thiopurines in inflammatory bowel disease

Frei, Pascal; Biedermann, Luc; Nielsen, Ole Haagen; Rogler, Gerhard

Abstract: The use of thiopurines as immunosuppression for the treatment of refractory or chronic active inflammatory bowel disease is established for both Crohn’s disease and ulcerative colitis. Nevertheless, many questions remain concerning the optimal treatment regimens of azathioprine, 6-mercaptopurine and thioguanine. We will briefly summarize dose recommendations, indications for thiopurine therapy and side effects which are relevant in clinical practice. We discuss some currently debated topics, including the combination of azathioprine and allopurinol, switching of thiopurine therapy in case of side effects, the use of azathioprine in pregnancy, the infection risk using thiopurines and the evidence when to stop thiopurines. Excellent reviews have been published on the thiopurine metabolic pathway which will not be discussed here in detail.

DOI: https://doi.org/10.3748/wjg.v19.i7.1040

Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-92854
Journal Article
Published Version

Originally published at:
Frei, Pascal; Biedermann, Luc; Nielsen, Ole Haagen; Rogler, Gerhard (2013). Use of thiopurines in inflammatory bowel disease. World Journal of Gastroenterology, 19(7):1040-1048.
DOI: https://doi.org/10.3748/wjg.v19.i7.1040
Use of thiopurines in inflammatory bowel disease

Pascal Frei, Luc Biedermann, Ole Haagen Nielsen, Gerhard Rogler

Pascal Frei, Luc Biedermann, Gerhard Rogler, Division of Gastroenterology and Hepatology, Department of Internal Medicine, University Hospital of Zurich, CH-8091 Zürich, Switzerland
Ole Haagen Nielsen, Department of Gastroenterology, Medical Section, Herlev Hospital, University of Copenhagen, DK-2730 Herlev, Denmark
Author contributions: Frei P wrote the initial draft of the manuscript; Nielsen OH and Rogler G contributed to the conception and design of the review and supervised the review; Biedermann L contributed to the supportive work and revision of the manuscript.
Correspondence to: Gerhard Rogler, MD, PhD, Division of Gastroenterology and Hepatology, Department of Internal Medicine, University Hospital of Zurich, Ramistrasse 100, CH-8091 Zürich, Switzerland. gerhard.rogler@usz.ch
Telephone: +41-44-2559519 Fax: +41-44-2559497
Received: June 5, 2012 Revised: July 16, 2012
Accepted: August 14, 2012
Published online: February 21, 2013

Abstract
The use of thiopurines as immunosuppression for the treatment of refractory or chronic active inflammatory bowel disease is established for both Crohn's disease and ulcerative colitis. Nevertheless, many questions remain concerning the optimal treatment regimens of azathioprine, 6-mercaptopurine and thioguanine. We will briefly summarize dose recommendations, indications for thiopurine therapy and side effects which are relevant in clinical practice. We discuss some currently debated topics, including the combination of azathioprine and allopurinol, switching of thiopurine therapy in case of side effects, the use of azathioprine in pregnancy, the infection risk using thiopurines and the evidence when to stop thiopurines. Excellent reviews have been published on the thiopurine metabolic pathway which will not be discussed here in detail.

© 2013 Baishideng. All rights reserved.

Key words: Thiopurines; Inflammatory bowel disease; Crohn’s disease; Ulcerative colitis; Immunosuppression; Infection

Frei P, Biedermann L, Nielsen OH, Rogler G. Use of thiopurines in inflammatory bowel disease. World J Gastroenterol 2013; 19(7): 1040-1048 Available from: URL: http://www.wjgnet.com/1007-9327/full/v19/i7/1040.htm DOI: http://dx.doi.org/10.3748/wjg.v19.i7.1040

DOSING AND MONITORING OF THIOPURINES

Thiopurines used for inflammatory bowel disease (IBD) treatment are azathioprine (AZA), 6-mercaptopurine (6-MP) and occasionally also 6-thioguanine (6-TG). The most commonly used thiopurine is AZA. The hepatic enzyme glutathione-S-transferase rapidly cleaves the prodrug AZA to 6-MP1, which is then metabolized in both liver and gut by several enzymes: (1) thiopurine-s-methyltransferase (TPMT) catalysing 6-MP to 6-methyl-MP (6-MMP); (2) xanthine oxidase catalyzing 6-MP to thiourea; and (3) hypoxanthine-guanine-phosphoribosyltransferase converting 6-MP to 6-thioguanine nucleotides (6-TGN). 6-TG is the final effector-metabolite2 which slowly accumulates in cells, and this metabolite is probably responsible for the delayed onset of action after 10-12 wk3.

Dose recommendations for AZA and 6-MP vary slightly between Western guidelines, with a daily dose of 2-3 mg/kg AZA and 1-1.5 mg/kg 6-MP recommended by the AGA4, and a daily dose of 1.5-2.5 mg/kg AZA and 0.75-1.5 mg/kg 6-MP recommended by the European Crohn’s and Colitis Organisation (ECCO)5. However, these recommendations do not necessarily hold true for other ethnicities. Several Japanese studies showed that Japanese IBD patients might reach sufficient 6-TGN values with substantially lower AZA and 6-MP dosages in adults6,7, children and adolescents8. If 6-TG is exceptionally used, it should be started at a much lower dosage of approximately 20 mg per day and should not exceed...
25 mg daily. However, it has to be strengthened that there are limited indications for use of 6-TG in IBD. 6-TG can be used in IBD patients who need a thiopurine for maintenance therapy but who are intolerant (or resistant) to 5-aminosalicylic acid (5-ASA) [in ulcerative colitis (UC)], AZA, 6-MP and methotrexate [in Crohn’s disease (CD)], and who do not have an option for surgery. Biological therapy could be considered as an alternative to 6-TG in this setting. The ECCO guideline concluded in 2006 that thioguanine cannot currently be recommended for maintenance of CD due to a high frequency of liver abnormalities (mainly nodular regenerative hyperplasia). According to the current literature, this might, however, be explained by the use of too high dosages of 6-TG resulting in 6-TGN levels exceeding 1000 pmol/8 × 10^8 erythrocytes which is much more than the target levels of 250-500 pmol/8 × 10^8 erythrocytes usually recommended when using AZA or 6-MP. Thus, if 6-TG is used as therapy for selected IBD patients, the 6-TGN levels should be controlled regularly combined with close monitoring of liver values, hematology and especially liver biopsy after one, three and then every three years. However, the histopathological diagnosis of nodular regenerative hyperplasia is difficult with a very poor inter-observer agreement, even among experts. Alternatively, non-invasive monitoring such as magnetic resonance imaging may be considered.

The dose recommendations as mentioned above are based on “Western” or “Caucasian” guidelines/evidence and are linked to the assumption that the TPMT pathway is “normal”. A diminished TPMT activity due to mutations of the TPMT gene leads to toxic levels of 6-TGN, which is a risk factor for drug-induced myelosuppression. TPMT mutations are not uncommon in Caucasian populations (mutation prevalence approximately 10%), but rarer in e.g., Chinese patients (5%) or even very rare in Japanese patients (1%). In patients with very high activity (homozygous mutant or compound heterozygote), an alternative drug should be considered or AZA starting dose might benefit from an increase in AZA dosage up to 3.0 mg/kg per day. Patients with a very high activity (heterozygote). In patients with low/absent activity (homozygous mutant or compound heterozygote), an alternative drug should be considered or AZA starting dose must be reduced by a 10-fold, administered thrice weekly, and under close monitoring. For patients with intermediate and low/absent TPMT activity, a therapeutic drug monitoring is recommended four weeks after treatment initiation. Patients with a very high activity might benefit from an increase in AZA dosage up to 3.0 mg/kg per day. Nevertheless, it is important to note that TPMT testing does not predict the long-term risk of myelosuppression or idiosyncratic adverse events such as fever, arthralgias, hepatitis or pancreatitis. Regular hematologic monitoring remains necessary, initially at least every second week until the patient has been on a stable dose for a month; in the later course at least every third month including a complete blood count including a differential count, especially to check the lymphocyte level but also platelets as well as amylase, and liver enzyme levels.

**TPMT MONITORING**

Despite the above mentioned measurement of thiopurine metabolites, TPMT genotyping (analysis of single nucleotide polymorphisms which influence the TPMT activity) and phenotyping (measuring the TMPT activity) can be applied before therapy with AZA or 6-MP is initiated. A recent study concluded that genotyping should be favoured for pre-treatment TPMT function since it is the more reliable test. This evaluation may help to identify slow metabolizers which are at risk of toxicity. Nevertheless, a recently meta-analysis stated that there is not yet enough evidence to advocate for routine TPMT testing. The United States Food and Drug Administration (FDA), but not the ECCO, recommends TPMT monitoring before the initiation of thiopurine therapy. In 2011, the first guideline for a thiopurine starting dose according to TPMT phenotype/genotype was developed. A reduction to 30%-70% of the full dose is recommended in patients with an intermediate activity (heterozygote). In patients with low/absent activity (homozygous mutant or compound heterozygote), an alternative drug should be considered or AZA starting dose must be reduced by a 10-fold, administered thrice weekly, and under close monitoring. For patients with intermediate and low/absent TPMT activity, a therapeutic drug monitoring is recommended four weeks after treatment initiation. Patients with a very high activity might benefit from an increase in AZA dosage up to 3.0 mg/kg per day. Nevertheless, it is important to note that TPMT testing does not predict the long-term risk of myelosuppression or idiosyncratic adverse events such as fever, arthralgias, hepatitis or pancreatitis. Regular hematologic monitoring remains necessary, initially at least every second week until the patient has been on a stable dose for a month; in the later course at least every third month including a complete blood count including a differential count, especially to check the lymphocyte level but also platelets as well as amylase, and liver enzyme levels.

**INDICATIONS FOR AZATHIOPRINE OR 6-MERCAPTOPURINE**

**No evidence for induction of remission in active IBD**

There is not enough evidence to recommend thiopurines...
for inducing remission in active IBD[32] based on five randomized controlled trials (RCTs) in active CD[33-37] and on two RCTs in active UC[38,39].

Prevention of relapse in quiescent IBD
In quiescent CD, AZA and 6-MP are effective at preventing a relapse based on two RCTs comparing AZA with placebo[33,37], and three RCTs comparing continued AZA vs withdrawal in patients who had been successfully maintained on AZA[40-42]. These studies showed a significantly higher relapse rate in the placebo groups as compared with the active treatment[21]. Additionally, a RCT evaluating glucocorticoid-dependent CD patients suggested that AZA was better than placebo at reducing the need for glucocorticoids[39].

In quiescent UC, AZA and 6-MP are effective at preventing a relapse based on three RCTs comparing AZA with placebo[36,39,44]. Overall, 60% of patients can be kept in remission if AZA is continued for 9-12 mo[32]. Similarly, another RCT which evaluated AZA withdrawal in 79 patients, who had been maintained on this drug for a minimum of 6 mo, showed a significant reduction on the relapse rate on AZA vs placebo after one year (36% vs 59%)[43].

Post-operative treatment of CD with thiopurines
Two RCTs in postoperative CD suggest that AZA or 6-MP is superior to placebo at preventing recurrence after surgery[34,47]. Furthermore, thiopurines administered postoperatively significantly reduced the clinical recurrence rates in population-based cohorts[46,49]. Thus, thiopurines might be a useful strategy, although anti-tumour necrosis factors (anti-TNFs) might be more efficient in preventing CD relapses postoperatively[50,51], especially among high risk patients (smokers, perforating disease or ≥ second operation)[40].

Treatment of fistulising CD with thiopurines
A meta-analysis in fistulizing CD demonstrates a significantly higher response rate to AZA and 6-MP as compared to placebo (54% vs 21%)[52]. The analyzed studies included patients with perianal, enterocutaneous, enteroen teric and rectovaginal fistulas. However, only in a minority of patients, AZA and 6-MP will lead to a complete fistula closure, but symptoms such as inflammation, discharge and discomfort are often substantially reduced. Since response of fistulas to these drugs will need several months, immunosuppression will be reasonable only as second-line treatment if fistulas don’t necessitate immediate surgery. Antibiotics are commonly used as first-line treatment and need to be started in parallel[55].

An overview of indications for thiopurines in IBD is given in Table 1.

ADVERSE EVENTS
AZA and 6-MP have similar side effects leading to discontinuation of therapy in 39% of patients in a large Dutch cohort[64], however, rates of intolerance are usually far lower. Most adverse events occur within the first 3 mo[53]. More than 50% of AZA intolerant patients tolerate 6-MP long-term[56]. Common side effects can be divided into dose-dependent and idiosyncratic side effects.

The major dose-dependent side effect of thiopurines is drug-induced myelosuppression which is observed in 2%-5% of Caucasian patients[57,58]. It can occur at any time with 25% of cases appearing beyond the first year[59]. Asian (or at least Japanese patients[60]) have a higher risk of myelotoxicity. It has been speculated that viral infections might contribute to myelosuppression, however, clear evidence is missing. Determining TPMT activity before starting thiopurines might avoid early myelosuppression, but regular haematological monitoring remains necessary in every patient.

Infectious complications are mostly dose-dependent, but sometimes idiosyncratic side effects. Infectious complications during thiopurine therapy can occur even in the absence of a dose-dependent leukopenia[62,64,65], especially when using a combination of thiopurines with corticosteroids which may induce a dose-dependent lymphocyte depletion. We recommend avoiding a lymphopenia of < 600/µL based on data from a rheumatological study[63]. Doing this, severe immunodeficiency is likely to be avoided[66]. Hepatotoxicity can manifest as early drug-induced hepatitis, nodular regenerative hyperplasia after years of therapy, sinusoidal dilatation or fibrosis[67]. It is important to note that IBD per se is a risk factor for nodular regenerative hyperplasia[62]. Hepatotoxicity induced by thiopurines seems more often dose dependent than idiosyncratic. In many patients, elevated transaminases respond to dose reduction. In a prospective monocentric cohort, 21 of 123 patients showed a transient or constant elevation of alanine aminotransferase levels[68]. If liver enzymes are repeatedly elevated, thiopurines need to be discontinued.

The most frequent idiosyncratic side effects are nausea, vomiting, and malaise in up to 15% of all patients[65]. Some advocate to slowly increase the dosage when thiopurine therapy is started, or to take it before night-time. However, the best way to start thiopurine therapy still has to be determined[67]. Other common side effects are headache, fatigue, anorexia, weight loss, stomatitis, alopecia, arthralgia, muscular weakness and rash, which may occur in more than 10% of patients. If these side effects are reported, it should be determined whether they disappear after dose reduction[62,65,69]. In case of arthralgias/myalgias upon AZA, a switch to 6-MP can be explored[57].

Pancreatitis is an important idiosyncratic side effect and occurs in up to 4% of the patients[40,69], especially during the first weeks of treatment[70]. A minor and asymptomatic increase in serum amylase (“pancreatic hyperenzymemia”) is frequently observed, but only poorly understood and not discussed in current guidelines. Some authors prefer to reduce dosing, or stop treatment
Table 1 Indications for thiopurines in inflammatory bowel disease

| Indication                                                                 | No indication                                                                 |
|---------------------------------------------------------------------------|-----------------------------------------------------------------------------|
| Crohn’s disease                                                           | Induction of remission in moderate (to severe) CD (any site of disease especially for extensive disease) |
| Maintaining remission in moderate (to severe) CD (any site of disease especially for extensive disease) | Maintenance of remission in moderate (to severe) CD (any site of disease especially for extensive disease) |
| Fistulizing CD in combination with antibiotics, if no early start of anti-TNF or surgery necessary | Postoperative prevention of CD recurrence (unless high-risk situation such as repeated surgery or current smoker) |
| Fistulizing CD in combination with anti-TNFs in case of severe CD (rapid step-up or top-down) | Fistulizing CD in combination with anti-TNFs in case of severe CD (rapid step-up or top-down) |
| Induction of remission in steroid-dependent UC                             | Induction of remission in steroid-dependent UC                                 |
| Induction of remission in UC with early relapse requiring steroids         | Induction of remission in UC with early relapse requiring steroids             |
| Induction of remission in UC with frequent flares requiring steroids       | Induction of remission in UC with frequent flares requiring steroids           |
| Maintaining remission in UC after induction of remission by ciclosporin, tacrolimus, or i.e. steroids | Maintaining remission in UC after induction of remission by ciclosporin, tacrolimus, or i.e. steroids |
| Acute or chronic refractory pouchitis                                      | Acute or chronic refractory pouchitis                                         |

CD: Crohn’s disease; UC: Ulcerative colitis; TNF: Tumour necrosis factor; 5-ASA: 5-aminosalicylic acid.

in case of lack of biochemical response\(^6^\). Thiopurines must be discontinued if amylase increase is associated with typical pain symptoms (i.e., toxic pancreatitis). After AZA-induced pancreatitis, a switch to 6-MP is not recommended since these patients are less likely to tolerate 6-MP\(^6^\). However, evidence against the use of 6-MP in AZA-induced pancreatitis is weak. As earlier outlined, 6-TG is a debated alternative to AZA and 6-MP in case of intolerance\(^9^\), which is, however, not recommended by some authors\(^6^,\(^7^\,\(^8^\).

WHEN AND HOW TO CHANGE THIOPURINE THERAPY IN CASE OF SIDE EFFECTS?

In the case of idiosyncratic side effects, it might be reasonable to change from AZA to 6-MP, as discussed above. Furthermore, in so-called preferential 6-MMP metabolizers which achieve only low 6-TGN levels due to high 6-MMP levels with associated hepatotoxicity, adding low-dose allopurinol as a XO inhibitor to dose-decreased AZA (25%-33% of intended dose\(^7^\), might switch the AZA metabolism to 6-TGN instead of 6MMP. Close monitoring of 6-TGN metabolites and hematology is in such cases necessary (weekly during the first month, then every other week for the next month)\(^7^\). This strategy often allows to reach therapeutic levels of 6-TGN and clinical remission, but may also to reduce or even alleviate nausea as one of the major early side effects in more than 80% of patients\(^7^,\(^9^\). Interestingly it seems possible to achieve higher 6-TGN and lower 6-MMP levels in preferential 6-MMP metabolizers by simply splitting the daily thiopurine dose\(^7^,\(^9^\) or by switching to 6-MP.

MALIGNANT COMPLICATIONS

Treatment with AZA/6-MP is associated with a potential risk of developing lymphoma\(^7^,\(^8^\), including hepatosplenic T-cell lymphoma (HSTCL).\(^9^,\(^10^\). Although the relative risk of lymphoma is increased four to five-fold\(^7\),\(^8^\), the absolute risk still remains rather small, and currently available data show that the benefits of thiopurines used in IBD greatly outweigh its risks\(^7\). The same holds true for non-melanoma skin cancer\(^7^,\(^8^\,\(^9^\,\(^10^\), which in a large cohort of 108,518 IBD patients collected from 1997 to 2009 was shown to occur significantly more often in IBD patients than controls\(^9^,\(^10^\), correlating with the length of receiving thiopurines. Of 32 cases of nonmelanoma skin cancer in a large cohort\(^6^\), only 5 cancers occurred in immunomodulator-naïve patients, but 9 and 18 cancers occurred in patients who had previously taken or were currently on thiopurine therapy. Based on these studies, a dermatologic exam should be considered before and regularly during immunomodulator therapy; especially in elderly patients. It should in this context be mentioned that skin protection is rather crucial.

WHEN SHOULD THIOPURINE MONOTHERAPY BE STOPPED?

When to stop a successful immunosuppression is one of the most difficult decisions in IBD therapy. Five studies focusing on this question were recently reviewed by Clarke and Regueiro\(^6^\). According to a randomized, controlled study from 2005, even CD patients who were in remission on AZA for at least 3.5 year profited from prolonged AZA therapy (relapse risk 8% vs 21% on placebo)\(^9^\). Similar results have been gained from other studies\(^6^\). Five years after stopping AZA, 3/4 of patients suffer from relapse. Nevertheless, a treatment stop seems justified since almost all patients re-treated with thiopurines were able to regain remission (23 of 24 patients; many with a combined short course of glucocorticoids)\(^9^\). Independent predictors for a flare are a C-reactive protein-level of > 20 mg/L, a haemoglobin-level < 12 mg/dL, and an absolute neutrophil count of > 4 x 10\(^9^\)/L at baseline. Since more than half of the patients with risk factors experienced a clinical flare-up within 24 mo (compared to only 15% of patients without negative predictors), a continuous course of thiopurine therapy is recommended for these patients.

In UC, several studies have shown that a prolonged AZA therapy helps to reduce the risk of relapse. Six months is certainly the minimum length of immunosuppression (with at least 3 mo disease-free interval off glu-
cocorticoids\textsuperscript{[84,85]}, but other studies showed that 18 mo is significantly better than 6 mo\textsuperscript{[81]}. In clinical practice, decision on the length of immunosuppressive therapy means weighing benefits of immunosuppression on IBD and risk of malignancies and other complications. The risk factors should be analysed before immunosuppression is stopped. Best candidates for stopping immunosuppression will probably be IBD patients in deep, prolonged remission with a short duration of time between diagnosis and immunomodulator treatment\textsuperscript{[81]}. Nonetheless, prospective RCTs are needed for the development of evidence-based tapering schemes regarding AZA and 6-MP treatment, both in CD as well as in UC.

**IMMUNOMODULATORS AND BIOLOGIC THERAPY**

Many experts in the field currently advocate a “top down” approach with early combination therapy for moderate to severe CD based on evidence from three infliximab and azathioprine studies in CD\textsuperscript{[86-88]}, including the famous SONIC trial\textsuperscript{[86]}. Nevertheless caution is advised as the number needed to treat for the combination therapy is 8, meaning that only one out of 8 patients will definitely benefit from the combination. For the combination of AZA and adalimumab, there are only retrospective and hardly convincing data\textsuperscript{[89]}. Future trials need to determine whether it is crucial to start with anti-TNFs and thiopurines at the same time, or whether a sequential addition of thiopurines to anti-TNFs will have the same effect in the patients experiencing a benefit from this combination.

Furthermore, there are not enough available data on how long the concomitant use of immunomodulators should be maintained in patients receiving infliximab. There are no studies which documented a sustained efficacy of concomitant use of immunomodulators beyond 6-12 mo\textsuperscript{[89,90]}. If therapy should be reduced, then AZA and not infliximab may be stopped. In the recently published prospective STORI (Stop Infliximab in Patients With Crohn’s Disease) study on infliximab stop in patients in remission under combined immunosuppression, nearly half of all patients suffered from relapse within 1 year when infliximab was stopped despite continuing azathioprine\textsuperscript{[92]}. In contrary, the risk of relapse after stopping AZA seems lower than after stopping infliximab. Thus, in a single referral center observational study on CD patients who stopped AZA after being in remission under combined AZA and infliximab for at least 6 mo, 15% of patients relapsed after 1 year\textsuperscript{[93]}. In alternative, thiopurine therapy for maintenance of remission can be stopped also need to be elucidated in future prospective trials. Risk communication with patients, but also referring physicians, about benefit, side effects and the above mentioned uncertainties remain challenging. Benefits are the quality of life gained by medically maintained remission; the avoidance of surgery (in CD and UC) and avoidance of colorectal cancer through efficient anti-inflammatory therapy. Risks are, however, (opportunistic) infections, lymphomas such as HSTCL and side-effects such as pancreatitis.

Accordingly, thiopurine therapy remains a hot topic in IBD.

**CONCLUSION**

Indications for use of thiopurines in IBD and ways to monitor therapy have been well established. In clinical practice, the possibility of 6-TGN measurement to monitor therapy seems underused. It is likely that broader use of TGN monitoring, and a combination of thiopurines with low dose allopurinol in case of inefficacy or side effects allows to (achieve or) maintain clinical remission in more patients. For the thiopurine/allopurinol combination, but also for 6-TG therapy, prospective trials to document the benefit (and risk) are urgently needed. Furthermore, more trials are needed to elucidate whether an early “top down” approach for combination of thiopurines with anti-TNF will bring a long-term benefit for patients as compared to a step-up approach in case of a non-response to thiopurines. Criteria when a successful thiopurine therapy for maintenance of remission can be stopped also need to be elucidated in future prospective trials. Risk communication with patients, but also referring physicians, about benefit, side effects and the above mentioned uncertainties remain challenging. Benefits are the quality of life gained by medically maintained remission; the avoidance of surgery (in CD and UC) and avoidance of colorectal cancer through efficient anti-inflammatory therapy. Risks are, however, (opportunistic) infections, lymphomas such as HSTCL and side-effects such as pancreatitis.

**REFERENCES**

1. Watanabe A, Hobara N, Nagashima H. Demonstration of enzymatic activity converting azathioprine to 6-mercaptopurine. Acta Med Okayama 1978; 32: 173-179 [PMID: 29442 DOI: 10.1097/00007691-199810000-00002]
2. Yatscoff RW, Aspeslet LJ. The monitoring of immunosuppressive drugs: a pharmacodynamic approach. Ther Drug Monit 1998; 20: 459-463 [PMID: 9780118]
3. Su C, Lichtenstein GR. Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurine. Gastroenterol Clin North Am 2004; 33: 209-234, viii [PMID: 15177535 DOI: 10.1016/j.gsc.2004.02.004 DOI: 10.1053/j.gastro.2006.01.047]
4. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006; 130: 935-939 [PMID: 16530531]
**Thiopurines in IBD**

5 Dignass A, Van Assche G, Lindsay JO, Lémann M, Söderholm J, Colombel JF, Danese S, D’Hoore A, Gassull M, Gomollón F, Hommes DW, Michetti P, O’Morain C, Oresland T, Windsor A, Stange EF, Travis SP. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Current management. *J Crohns Colitis* 2010; 4: 28-62 [PMID: 21122849 DOI: 10.1016/j.crohns.2009.12.002]

6 Andoh A, Tsuikawa T, Ban H, Hashimoto T, Bamba S, Ogawa A, Sasaki M, Saito Y, Fujiyama Y. Monitoring 6-thioguanine nucleotide concentrations in Japanese patients with inflammatory bowel disease. *J Gastroenterol Hepatol* 2008; 23: 1737-1737 [PMID: 18662197 DOI: 10.1111/j.1440-1746.2008.05419.x]

7 Komiyama T, Yajima T, Kubota R, Iwao Y, Sakuraba A, Funakoshi S, Negishi G, Minami I, Tanaka Y, Maeh H, Hibi T. Lower doses of 6-mercaptopurine/azathioprine bring enough clinical efficacy and therapeutic concentration of erythropoetin 6-mercaptopurine metabolite in Japanese IBD patients. *J Crohns Colitis* 2008; 2: 315-321 [PMID: 21172230 DOI: 10.1016/j.crohns.2008.05.002]

8 Ohtsu Y, Arai K, Aoyagi Y, Fuji T, Yamakawa Y, Ohtani K, Ikuse T, Baba Y, Inage K, Eudo T, Suzuki R, Nagata S, Shimizu T. Monitoring 6-thioguanine nucleotide concentrations in Japanese children and adolescents with inflammatory bowel disease. *J Gastroenterol Hepatol* 2010; 25: 1626-1630 [PMID: 20880170 DOI: 10.1111/j.1440-1746.2010.06364.x]

9 Seinen ML, van Assendelft DP, Mulder CJ, de Boer NK. Dosing 6-thioguanine in inflammatory bowel disease: expert-based guidelines for daily practice. *J Gastrointestin Liver Dis* 2010; 19: 291-294 [PMID: 20922914]

10 Derijks LJ, Gilissen LP, de Boer NK, Mulder CJ. 6-Thioguanine-related hepatotoxicity in patients with inflammatory bowel disease: dose or level dependent? *J Hepatol* 2006; 44: 821-822 [PMID: 16487625 DOI: 10.1016/j.jhep.2005.11.049]

11 Gilissen LP, Derijks LJ, Driessen A, Bos LP, Hooymans PM, Stockbrügger RW, Engels LG. Toxicity of 6-thioguanine: no hepatotoxicity in a series of IBD patients treated with long-term, low dose 6-thioguanine. Some evidence for dose or metabolite level dependent effects? *Dig Liver Dis* 2007; 39: 156-159 [PMID: 17188950 DOI: 10.1016/j.dld.2006.10.007]

12 Rogler G. Gastrointestinal and liver adverse effects of drugs used for treating IBD. *Best Pract Res Clin Gastroenterol* 2010; 24: 157-165 [PMID: 20227029 DOI: 10.1016/j.bpg.2010.01.011]

13 de Boer NK, Zondervan PE, Gilissen LP, den Hartog G, Westerbeek LS-569 [PMID: 10.1016/j.crohns.2011.11.014]

14 Booth RA, Ansari MT, Loit E, Trico AC, Weeks L, Doutce S, Skidmore B, Burs M, Sy R, Karsh J. Assessment of thiopurine S-methyltransferase activity in patients under steady thiopurine therapy. *Br J Pharmacol* 2010; 160: 1083-1091 [PMID: 20590602 DOI: 10.1111/j.1476-5381.2010.07371.x]

15 Hindorf U, Appell ML. Genotyping should be considered the primary choice for pre-treatment evaluation of thiopurine methyltransferase function. *J Crohns Colitis* 2012; 6: 1578-1584 [PMID: 22625172 DOI: 10.1016/j.jcc.2012.04.009.x]

16 Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, Yee SW, Stein CM, Carrillo M, Evans WE, Klein TE. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. *Clin Pharmacol Ther* 2011; 89: 357-391 [PMID: 21270794 DOI: 10.1038/clp.2010.320]

17 Colombel JF, Ferrari N, Debuesyer H, Marete P, Gendre JP, Bonaz B, Souile JC, Modigliani R, Touze Y, Catala P, Libersa C, Broy F. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn’s disease and severe myelosuppression during azathioprine therapy. *Gastroenterology* 2000; 118: 1025-1030 [PMID: 10833476]

18 Colombel JF, Loftus EV, Tremaine WJ, Pemberton JH, Wollf BG, Young-Fadok T, Harmsen WS, Schleck CD, Sandborn WJ. Early postoperative complications are not increased in patients with Crohn’s disease treated perioperatively with infliximab or immunosuppressive therapy. *Am J Gastroenterol* 2004; 99: 878-883 [PMID: 15128354 DOI: 10.1111/j.1572-0241.2004.04146.x]
30 Sandborn WJ. A review of immune modulator therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol 1996; 91: 423-433 [PMID: 8633486]

31 Glück T, Kießmann B, Grohmann M, Falk W, Straub RH, Schölmerich J. Immune status and risk for infection in patients receiving chronic immunosuppressive therapy. J Rheumatol 2005; 32: 1473-1480 [PMID: 16078322]

32 Khan KJ, Dubinsky MC, Ford AC, Ullman TA, Talley NJ. Moayyedi P. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 630-642 [PMID: 21407186 DOI: 10.1038/ajg.2011.64]

33 Candy S, Wright J, Gerber M, Adams G, Gerg M, Good RA, Cohen RD, Present DH. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 2004; 127: 723-729 [PMID: 15362027 DOI: 10.1053/j.gastro.2004.06.002]

34 Ewe K, Press AG, Singe CC, Stuffer M, Ueberschaer B, Hommel G, Meyer zum Büschenfelde KH. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology 1993; 105: 367-372 [PMID: 8335191]

35 Oren R, Moshkovitz M, Odes S, Becker S, Keter D, Pomeranz I, Shirin C, Reisfeld I, Broide E, Lavy A, Fich A, Eliakim R, Patz J, Villa Y, Arber N, Gilat T. Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial. Am J Gastroenterol 1997; 92: 2203-2209 [PMID: 9399753]

36 Reimisch W, Panés J, Lémann M, Schreiber S, Feagan B, Schmidt S, Sturniolo GC, Mikhailova T, Alexeeva O, Sanna P, Déjardin N, Bhatia KL, Sood N, Kaushal V. Role of azathioprine for inflammatory bowel disease: azathioprine, 6-mercaptopurine, and methotrexate. Inflammatory bowel disease: azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis. Am J Gastroenterol 2009; 104: 2089-2096 [PMID: 19568226 DOI: 10.1038/ajg.2009.301]

37 Jewell DP. Truelove SC. Azathioprine in ulcerative colitis: final report on controlled therapeutic trial. Br Med J 1974; 4: 627-630 [PMID: 4441827 DOI: 10.1136/bmj.4.5945.627]

38 Sood A, Moshkovitz M, Odes S, Soule JC, Bhatia KL, Sood N, Malhotra V. The beneficial effect of azathioprine on maintenance of remission in severe ulcerative colitis. J Gastroenterol 2002; 37: 270-274 [PMID: 11993510 DOI: 10.1007/s005350200034]

39 Hawthorne AB, Logan RF, Hawkey CJ, Foster PN, Axon AT, Swarbrick ET, Scott BB, Lennard-Jones JE. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 1992; 305: 20-22 [PMID: 1638191 DOI: 10.1136/bmj.305.6844.20]

40 D’Haens GR, Vermeire S, Van Assche G, Noman M, Aarden I, Van Olmen G, Rutgeerts P. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroenterology 2008; 135: 1123-1129 [PMID: 18727929 DOI: 10.1015/j.gastro.2008.07.010]

41 Hanauer SB, Korelitz BI, Rutgeerts P, Peppercorn MA, Thisted RA, Cohen RD, Present DH. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 2004; 127: 723-729 [PMID: 15362027 DOI: 10.1053/j.gastro.2004.06.002]

42 Peyrin-Biroulet L, Dellente P, Ardizzzone S, D’Haens G, Hanauer SB, Herfath H, Lémann M, Colombel JF. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn’s disease: a meta-analysis. Am J Gastroenterol 2009; 104: 2089-2096 [PMID: 19568226 DOI: 10.1038/ajg.2009.301]

43 Reinsch W, Schroeder KW, Harrison JM, Zinsmeister AR. A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn’s colitis and ileocolitis. J Clin Gastroenterol 1994; 19: 278-282 [PMID: 7876505 DOI: 10.1097/00004836-199412000-00003]

44 Jewell DP. Truelove SC. Azathioprine in ulcerative colitis: final report on controlled therapeutic trial. Br Med J 1974; 4: 627-630 [PMID: 4441827 DOI: 10.1136/bmj.4.5945.627]

45 Nielsen OH, Rogler G, Hahnloser D, Thomsen OD. Diagnosis and management of fistulizing Crohn's disease. Nat Clin Pract Gastroenterol Hepatol 2009; 6: 92-106 [PMID: 19153563 DOI: 10.1038/ncpgasthep1340]

46 Jharp B, Seinen ML, de Boer NK, van Ginkel JR, Linksens RK, Koppelman JC, Mulder CJ, van Bodegraven AA. Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts. Inflamm Bowel Dis 2010; 16: 1541-1549 [PMID: 20155846 DOI: 10.1002.ibd.21221]

47 Hindorf U, Lindqvist M, Hildebrand H, Fagerberg U, Almer S. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease. Aliment Pharmacol Ther 2006; 24: 331-342 [PMID: 16842460 DOI: 10.1111/j.1365-2036.2006.02977.x]

48 Hindorf U, Johansson M, Eriksson A, Kvifors E, Almer SH. www.wjgnet.com
Ardizzzone S. Maintenance treatment with azathioprine in ulcerative colitis: outcome and predictive factors after drug withdrawal. *Am J Gastroenterol* 2009; 104: 2760-2767 [PMID: 19623172 DOI: 10.1038/ajg.2009.410]

Lobel EZ, Korellitz BI, Xuereb MA, Panagopoulos G. A search for the optimal duration of treatment with 6-mercaptopurine for ulcerative colitis. *Am J Gastroenterol* 2004; 99: 462-465 [PMID: 15056086 DOI: 10.1111/j.1572-0241.2004.04104.x]

Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D’Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rutgeerts P. Infliximab, or combination therapy for Crohn’s disease. *N Engl J Med* 2010; 362: 1383-1395 [PMID: 20393175 DOI: 10.1056/NEJMoa0904492]

D’Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, De Vos M, van Deventer S, Stitt L, Donner A, Vermeire S, Van de Mierop FJ, Coche JC, van der Woude J, Ochsenuhlt T, van Bodegraven AA, Van Hoogem JP, Lambrecht GL, Mana F, Rutgeerts P, Feagan BG, Hommes D. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. *Lancet* 2008; 371: 660-667 [PMID: 18295023]

Lémann M, Mary JY, Dubois B, Veyrac M, Dupas JL, Delchier JC, Laharie D, Moreau J, Cadiot G, Picon L, Bourreille A, Sobhani I, Colombel JF. Infliximab plus azathioprine for steroid-dependent Crohn’s disease patients: a randomized placebo-controlled trial. *Gastroenterology* 2006; 130: 1054-1061 [PMID: 16618399 DOI: 10.1053/j.gastro.2006.02.014]

Reenaers C, Louis E, Belaiche J, Keshav S, Travis S. Immunosuppressive co-treatment with adalimumab (ADA) may be more effective than ADA monotherapy for maintaining remission in Crohn’s disease (CD). *J Crohns Colitis* 2012; 6 Suppl 1: S8 [DOI: 10.1016/S1877-9494(12)60016-6]

Lichtenstein GR, Diamond RH, Wagner CL, Fasanmade AA, Olson AD, Marano CW, Johns J, Lang Y, Sandborn WJ. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. *Aliment Pharmacol Ther* 2009; 30: 210-226 [PMID: 19392858 DOI: 10.1111/j.1365-2036.2009.04027.x]

Van Assche G, Magdelaine-Beuzelin C, D’Haens G, Baert F, Noman M, Vermeire S, Ternant D, Watier H, Painchaud G, Rutgeerts P. Withdrawal of immunosuppression in Crohn’s disease treated with scheduled infliximab maintenance: a randomized trial. *Gastroenterology* 2008; 134: 1861-1868 [PMID: 18440315 DOI: 10.1053/j.gastro.2008.03.004]

Louis E, Mary JY, Vernier-Massouille G, Grimaud JC, Bouchon Y, Laharie D, Dupas JL, Pillant H, Picon L, Veyrac M, Flamant M, Savoye G, Jian R, Devos M, Porcher R, Painchaud G, Piver E, Colombel JF, Lemann M. Maintenance of remission among patients with Crohn’s disease on antiimmunobiotic therapy after infliximab therapy is stopped. *Gastroenterology* 2012; 142: 63-70.e5; quiz e31 [PMID: 21945953]

Oussalah A, Chevaux JB, Fay R, Sandborn WJ, Bigard MA, Peyrin-Biroulet L. Predictors of infliximab failure after azathioprine withdrawal in Crohn’s disease treated with combination therapy. *Am J Gastroenterol* 2010; 105: 1142-1149 [PMID: 20389206]

Francell A, Dyant A, Bodian C, Rubin P, Chapman M, Present DH. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. *Gastroenterology* 2003; 124: 9-17 [PMID: 12512024 DOI: 10.1053/gast.2003.50014]

Goldstein LH, Dolinsky G, Greenberg R, Schaefer C, Cohen-Kerem R, Diav-Citrin O, Malm H, Reuvers-Lodewijks ME, Rost van Tonningen-van Driel MM, Arnon J, Ornny A, Clementi M, Di Gianantonio E, Koren G, Braunstein R, Berkovitch M. Pregnancy outcome of women exposed to azathioprine during pregnancy. *Birth Defects Res A Clin Mol Teratol* 2007; 79: 696-701 [PMID: 17847119 DOI: 10.1002/bdra.20599]

Cleary BJ, Källén B. Early pregnancy azathioprine use and pregnancy outcomes. *Birth Defects Res A Clin Mol Teratol* 2009, 85: 647-654 [PMID: 19343728 DOI: 10.1002/bdra.20583]

Langagergaard V, Pedersen L, Gislum M, Nørgaard B, Sørensen HT. Birth outcome in women treated with azathioprine during pregnancy. *Teratol, Prenat Diagn* 2012; 32: 421-426 [PMID: 22165730 DOI: 10.1002/trdi.20637]

Berkovitch M. Pregnancy outcome of women exposed to methotrexate or mercaptopurine during pregnancy: A Danish nationwide cohort study. *Aliment Pharmacol Ther* 2007; 25: 73-81 [PMID: 17229222 DOI: 10.1002/bdra.20583]

Christensen LA, Dahlerup JF, Nielsen MJ, Fællingborg JF, Schmiegelow K. Azathioprine treatment during lactation. *Aliment Pharmacol Ther* 2008; 28: 1209-1213 [PMID: 18761704]

Peyrin-Biroulet L, Oussalah A, Robin X, Sparrow MP. The use of azathioprine in Crohn’s disease during pregnancy and in the post-operative setting: a worldwide survey of experts. *Aliment Pharmacol Ther* 2011; 33: 707-713 [PMID: 21251032 DOI: 10.1111/j.1365-2036.2011.04577.x]

P- Reviewers Fries W, Cheon JH
S- Editor Shi ZF
L- Editor A
E- Editor Xiong L